Case Report

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe

Linda A. Mandikiyana Chirimuta, Margaret J. Pascoe, Sara Lowe
Southern African Journal of HIV Medicine | Vol 23, No 1 | a1435 | DOI: https://doi.org/10.4102/sajhivmed.v23i1.1435 | © 2022 Linda A. Mandikiyana Chirimuta, Margaret J. Pascoe, Sara Lowe | This work is licensed under CC Attribution 4.0
Submitted: 13 July 2022 | Published: 26 October 2022

About the author(s)

Linda A. Mandikiyana Chirimuta, Newlands Clinic, Ruedi Luethy Foundation, Harare, Zimbabwe
Margaret J. Pascoe, Newlands Clinic, Ruedi Luethy Foundation, Harare, Zimbabwe
Sara Lowe, Newlands Clinic, Ruedi Luethy Foundation, Harare, Zimbabwe


Share this article

Bookmark and Share

Abstract

We report two cases of dolutegravir (DTG) resistance in highly treatment experienced patients. Monitoring for treatment failure and adherence support is important in highly treatment experienced patients taking DTG.

What this study adds: Dolutegravir is the mainstay of HIV treatment programmes and emergence of drug resistance to DTG is of public health relevance.


Keywords

HIV drug resistance; dolutegravir; integrase strand inhibitor; antiretroviral treatment; HIV

Metrics

Total abstract views: 619
Total article views: 547


Crossref Citations

No related citations found.